Back to Search
Start Over
New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome.
- Source :
- PLoS Pathogens; 12/21/2023, Vol. 19 Issue 12, p1-14, 14p
- Publication Year :
- 2023
-
Abstract
- This article explores the relationship between certain cancer therapies and the risk of fungal infections. It focuses on three types of therapies: BTK inhibitors, PI3K inhibitors, and CD-52 monoclonal antibodies. These therapies have been found to increase susceptibility to invasive fungal infections (IFIs) by impairing the immune response or depleting T cells. The article suggests that repurposing existing cancer therapeutics could be a strategy to address the limited options for antifungal treatments. It also discusses the potential of using targeted therapies, immunotherapy, and interferon-gamma in combination with antifungals to improve outcomes. Further research is needed to evaluate the effectiveness of these approaches. [Extracted from the article]
- Subjects :
- MYCOSES
MONOCLONAL antibodies
T cells
CANCER treatment
BRUTON tyrosine kinase
Subjects
Details
- Language :
- English
- ISSN :
- 15537366
- Volume :
- 19
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- PLoS Pathogens
- Publication Type :
- Academic Journal
- Accession number :
- 174388992
- Full Text :
- https://doi.org/10.1371/journal.ppat.1011845